The mTORC1 inhibitor everolimus prevents and treats E?-Myc lymphoma by restoring oncogene-induced senescence

Wall, Meaghan; Poortinga, Gretchen; Stanley, Kym L.; Lindemann, Ralph K.; Bots, Michael; Chan, Christopher J; Bywater, Megan J.; Kinross, Kathryn M.; Astle, Megan V.; Waldeck, Kelly; Hannan, Katherine; Shortt, Jake; Smyth, Mark J; Lowe, Scott W.; Hannan, Ross; Pearson, Richard B; Johnstone, Ricky; McArthur, Grant

doi:10.1158/2159-8290.CD-12-0404

A change is coming. Click to see a sneak peek of the new Open Research Repository.

The mTORC1 inhibitor everolimus prevents and treats E?-Myc lymphoma by restoring oncogene-induced senescence

Request a Copy

link to publisher version

Altmetric Citations

Wall, Meaghan; Poortinga, Gretchen; Stanley, Kym L.; Lindemann, Ralph K.; Bots, Michael; Chan, Christopher J; Bywater, Megan J.; Kinross, Kathryn M.; Astle, Megan V.; Waldeck, Kelly; Hannan, Katherine ; Shortt, Jake; Smyth, Mark J; Lowe, Scott W.; Hannan, Ross; Pearson, Richard B; Johnstone, Ricky; McArthur, Grant

Description

MYC deregulation is common in human cancer. IG-MYC translocations that are modeled in EμMyc mice occur in almost all cases of Burkitt lymphoma as well as in other B-cell lymphoproliferative disorders. Deregulated expression of MYC results in increased mT

Collections	ANU Research Publications
Date published:	2013
Type:	Journal article
URI:	http://hdl.handle.net/1885/67129
Source:	Cancer Discovery
DOI:	10.1158/2159-8290.CD-12-0404

Download

File	Description	Size	Format	Image
01_Wall_The_mTORC1_inhibitor_2013.pdf		8.75 MB	Adobe PDF	Request a copy

Show full item record

The mTORC1 inhibitor everolimus prevents and treats E?-Myc lymphoma by restoring oncogene-induced senescence

Altmetric Citations

Description

Download